Skip to content

Comparison of Lens Fit and Lens Power of a New Contact Lens to Two Marketed Contact Lenses in a Population of Soft Contact Lens Wearers

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01244529
Enrollment
41
Registered
2010-11-19
Start date
2010-09-01
Completion date
2010-11-01
Last updated
2018-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Brief summary

The purpose of this study is to evaluate the comparability of lens fit and lens power of a new contact lens to the lens fit and lens power of two marketed lenses.

Interventions

DEVICEgaly A Plus

galyfilcon A Plus, BC: 8.3 or 8.7

DEVICEseno A

senofilcon A, BC:8.4 or 8.8

DEVICEgaly A

galyfilcon A , BC: 8.3 or 8.7

Sponsors

Johnson & Johnson Vision Care, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* Must be at least 18 years of age and no more than 55 years of age. * Must sign written informed consent. * Optimal spherical equivalent distance correction must be between -1.00 and -6.00 diopters. * Have spectacle astigmatism ≤ -0.75 diopter cylinder in both eyes. * Must have visual acuity best correctable to 20/25+3 or better for each eye. * Must appear able and willing to adhere to the instructions set forth in this clinical protocol. * Have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having: No evidence of lid abnormality or infection; No conjunctival abnormality or infection; No clinical significant slit lamp findings, (i.e., oedema, staining, scarring, vascularization, infiltrates or abnormal opacities); No other active ocular disease. * The subject is a current spherical soft contact lens wearer (defined as a minimum of 6 hours of daily wear for a minimum of 1 month prior to the study) and willing to wear the study lenses on a daily wear basis (defined as a minimum of 6 hours of wear per day at least five days of the week) for the duration of the study.

Exclusion criteria

* Any systemic illness which would contraindicate lens wear or the medical treatment of which would affect vision or successful lens wear. * Any previous eye surgery involving the anterior segment. * Pre-existing ocular disease that would preclude contact lens fitting. * Abnormal lacrimal secretions. * Keratoconus or other corneal irregularity. * Pregnancy, lactating or planning a pregnancy at the time of enrollment. * Participation in any concurrent clinical trial. * Subject's habitual contact lens type is toric or multifocal. * Require any concurrent ocular medication.

Design outcomes

Primary

MeasureTime frameDescription
Lens Centration Acceptanceafter 15 minutes of contact lens wearInvestigator evaluated as acceptable (centered/slightly decentered) or unacceptable (substantially decentered). Number of eyes in each category will be reported by lens. This is an aggregate reporting of the lenses, combining the different base curves into a category by lens type. This is done per protocol, due to this primary outcome not being stratified by base curve.
Primary Gaze Lens Movementafter 15 minutes of contact lens wearInvestigator evaluated as acceptable (minimal or moderate movement) or unacceptable (insufficient or excessive movement). Percent of eyes in each category will be evaluated.
Fit Acceptabilityafter 15 minutes of contact lens wearInvestigator evaluated lens fit using a six point scale: 5-optimal...3-borderline acceptable...2-unacceptable. Percent of eyes in each category will be evaluated.

Secondary

MeasureTime frameDescription
New Lens Power Fit Match to Control Lensesafter 15 minutes of contact lens wearThe lens power fit of test lenses will be compared to control lenses to determine if the power matches. Percent of eyes with exact power fit will be evaluated.

Countries

United Kingdom

Participant flow

Participants by arm

ArmCount
All Subjects
All subjects who where enrolled wore all intervention lenses throughout the course of the study. The specific lenses used include the following: senofilcon A (control) soft contact lens with 8.8 base; senofilcon A (control) soft contact lens with 8.4 base curve; galyfilcon A (control) soft contact lens with 8.7 base curve; galyfilcon A (control) soft contact lens with 8.3 base curve; galyfilcon A Plus (test) soft contact lens with 8.7 base curve; galyfilcon A Plus (test) soft contact lens with 8.3 base curve.
41
Total41

Baseline characteristics

CharacteristicAll Subjects
Age, Continuous34.0 years
STANDARD_DEVIATION 12.4
Region of Enrollment
United Kingdom
41 participants
Sex: Female, Male
Female
21 Participants
Sex: Female, Male
Male
20 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 41
serious
Total, serious adverse events
0 / 41

Outcome results

Primary

Fit Acceptability

Investigator evaluated lens fit using a six point scale: 5-optimal...3-borderline acceptable...2-unacceptable. Percent of eyes in each category will be evaluated.

Time frame: after 15 minutes of contact lens wear

Population: Analysis was on those completed subjects who were enrolled, randomized, and assigned to a study arm.

ArmMeasureGroupValue (NUMBER)
Galyfilcon A Plus (Test)Fit AcceptabilityAcceptable Fit90 percentage of eyes
Galyfilcon A Plus (Test)Fit AcceptabilityUnacceptable Fit10 percentage of eyes
Galyfilcon A (Control)Fit AcceptabilityAcceptable Fit90 percentage of eyes
Galyfilcon A (Control)Fit AcceptabilityUnacceptable Fit10 percentage of eyes
Senofilcon AFit AcceptabilityAcceptable Fit95 percentage of eyes
Senofilcon AFit AcceptabilityUnacceptable Fit5 percentage of eyes
Galyfilcon AP 8.7 BCFit AcceptabilityAcceptable Fit83 percentage of eyes
Galyfilcon AP 8.7 BCFit AcceptabilityUnacceptable Fit17 percentage of eyes
Galyfilcon A 8.7 BCFit AcceptabilityAcceptable Fit71 percentage of eyes
Galyfilcon A 8.7 BCFit AcceptabilityUnacceptable Fit29 percentage of eyes
Senofilcon A 8.8 BCFit AcceptabilityAcceptable Fit80 percentage of eyes
Senofilcon A 8.8 BCFit AcceptabilityUnacceptable Fit20 percentage of eyes
Primary

Lens Centration Acceptance

Investigator evaluated as acceptable (centered/slightly decentered) or unacceptable (substantially decentered). Number of eyes in each category will be reported by lens. This is an aggregate reporting of the lenses, combining the different base curves into a category by lens type. This is done per protocol, due to this primary outcome not being stratified by base curve.

Time frame: after 15 minutes of contact lens wear

Population: Analysis was on those completed subjects who were enrolled, randomized, and assigned to a study arm.

ArmMeasureGroupValue (NUMBER)
Galyfilcon A Plus (Test)Lens Centration AcceptanceAcceptable centration74 eyes
Galyfilcon A Plus (Test)Lens Centration AcceptanceUnacceptable centration8 eyes
Galyfilcon A (Control)Lens Centration AcceptanceAcceptable centration62 eyes
Galyfilcon A (Control)Lens Centration AcceptanceUnacceptable centration20 eyes
Senofilcon ALens Centration AcceptanceAcceptable centration69 eyes
Senofilcon ALens Centration AcceptanceUnacceptable centration13 eyes
Primary

Primary Gaze Lens Movement

Investigator evaluated as acceptable (minimal or moderate movement) or unacceptable (insufficient or excessive movement). Percent of eyes in each category will be evaluated.

Time frame: after 15 minutes of contact lens wear

Population: Analysis was on those completed subjects who were enrolled, randomized, and assigned to a study arm.

ArmMeasureGroupValue (NUMBER)
Galyfilcon A Plus (Test)Primary Gaze Lens MovementAcceptable movement93 percentage of eyes
Galyfilcon A Plus (Test)Primary Gaze Lens MovementUnacceptable movement7 percentage of eyes
Galyfilcon A (Control)Primary Gaze Lens MovementAcceptable movement93 percentage of eyes
Galyfilcon A (Control)Primary Gaze Lens MovementUnacceptable movement7 percentage of eyes
Senofilcon APrimary Gaze Lens MovementAcceptable movement100 percentage of eyes
Senofilcon APrimary Gaze Lens MovementUnacceptable movement0 percentage of eyes
Galyfilcon AP 8.7 BCPrimary Gaze Lens MovementAcceptable movement93 percentage of eyes
Galyfilcon AP 8.7 BCPrimary Gaze Lens MovementUnacceptable movement7 percentage of eyes
Galyfilcon A 8.7 BCPrimary Gaze Lens MovementAcceptable movement90 percentage of eyes
Galyfilcon A 8.7 BCPrimary Gaze Lens MovementUnacceptable movement10 percentage of eyes
Senofilcon A 8.8 BCPrimary Gaze Lens MovementAcceptable movement98 percentage of eyes
Senofilcon A 8.8 BCPrimary Gaze Lens MovementUnacceptable movement2 percentage of eyes
Secondary

New Lens Power Fit Match to Control Lenses

The lens power fit of test lenses will be compared to control lenses to determine if the power matches. Percent of eyes with exact power fit will be evaluated.

Time frame: after 15 minutes of contact lens wear

Population: Analysis was on those completed subjects who were enrolled, randomized, and assigned to a study arm.

ArmMeasureGroupValue (NUMBER)
Galyfilcon A Plus (Test)New Lens Power Fit Match to Control LensesLens Power the Same98 percentage of eyes
Galyfilcon A Plus (Test)New Lens Power Fit Match to Control LensesLens Power Not the Same2 percentage of eyes
Galyfilcon A (Control)New Lens Power Fit Match to Control LensesLens Power Not the Same2 percentage of eyes
Galyfilcon A (Control)New Lens Power Fit Match to Control LensesLens Power the Same98 percentage of eyes
Senofilcon ANew Lens Power Fit Match to Control LensesLens Power the Same98 percentage of eyes
Senofilcon ANew Lens Power Fit Match to Control LensesLens Power Not the Same2 percentage of eyes
Galyfilcon AP 8.7 BCNew Lens Power Fit Match to Control LensesLens Power the Same98 percentage of eyes
Galyfilcon AP 8.7 BCNew Lens Power Fit Match to Control LensesLens Power Not the Same2 percentage of eyes

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026